For US Healthcare Professionals
Prescribing Information
POSLUMA logo

POSLUMA:
Precision PSMA targeting

For imaging of newly diagnosed or recurrent prostate cancer

Mechanism of action
Low urinary bladder activity
Back to Top
Mechanism of action
Low urinary bladder activity

MECHANISM OF ACTION

POSLUMA has a precise
PSMA-targeting mechanism of action1,2

PSMA receptor
  • The molecular structure of POSLUMA uses radiohybrid™ technology, with a DOTAGA complex with nonradioactive gallium and radioactive F 18 covalently bound to silicon1,5
  • The DOTAGA complex in radiohybrid™ technology can be labeled with alpha- or beta-emitting radiometals5,6
Question mark icon

IS SOMETHING OBSCURING YOUR PSMA SCANS?

Activity in the urinary bladder can impact the assessment of tumors and lymph nodes local to the prostate region (the most common site of recurrence), sometimes producing halo artifacts that deteriorate image quality.7-9

LOW URINARY BLADDER ACTIVITY

With POSLUMA, urinary bladder activity interference is limited, which may enhance clinical visualization7,10

POSLUMA DEMONSTRATED LOW URINARY BLADDER ACTIVITY1,10

Line graph showing low urinary bladder activity with POSLUMA
pinch-zoom

In preclinical and Phase 1 studies, low radioactivity in the urinary bladder improved tumor-to-background ratio and may enhance confidence in image interpretation in the prostate bed and surrounding areas.7,10

Images of prostate-bed visualization following administration of POSLUMA10

PET image of healthy volunteer 1 minute after administration of POSLUMA

1 min

PET image of healthy volunteer 32 minutes after administration of POSLUMA

32 min

START PET IMAGING
~60 MINUTES POST ADMINISTRATION1

PET image of healthy volunteer 48 minutes after administration of POSLUMA

48 min

PET image of healthy volunteer 76 minutes after administration of POSLUMA

76 min

PET image of healthy volunteer 150 minutes after administration of POSLUMA

150 min

PET image of healthy volunteer 220 minutes after administration of POSLUMA

220 min

PET images of a healthy volunteer after administration of POSLUMA.

The first scan session was at 1 to 90 minutes after injection, the second was at 150 to 178 minutes, and the third was at 220 to 248 minutes. Subject was permitted to leave PET scanner and void urine between sessions.

POSLUMA PET scan showing uptake in the internal iliac lymph node

See POSLUMA case studies

Discover POSLUMA in action

View Case Studies

Next Up

SPOTLIGHT Study

Explore related content

Map iconFind an imaging center
Form iconStay informed

References: 1. POSLUMA. Package insert. Blue Earth Diagnostics Ltd; 2023. 2. Donin NM, Reiter RE. Why targeting PSMA is a game changer in the management of prostate cancer. J Nucl Med. 2018;59(2):177-182. doi:10.2967/jnumed.117.191874 3. Werner RA, Derlin T, Lapa C, et al. 18F-labeled, PSMA-targeted radiotracers: leveraging the advantages of radiofluorination for prostate cancer molecular imaging. Theranostics. 2020;10(1):1-16. doi:10.7150/thno.37894 4. Rowe SP, Drzezga A, Neumaier B, et al. Prostate-specific membrane antigen–targeted radiohalogenated PET and therapeutic agents for prostate cancer. J Nucl Med. 2016;57(suppl 3):90S-96S. doi:10.2967/jnumed.115.170175 5. Jani AB, Ravizzini GC, Gartrell BA, et al. Diagnostic performance and safety of 18F-rhPSMA-7.3 PET in men with suspected prostate cancer recurrence: results from a phase 3, prospective, multicenter study (SPOTLIGHT). J Urol. Published online April 26, 2023. doi:10.1097/JU.0000000000003493 6. Wurzer A, Di Carlo D, Schmidt A, et al. Radiohybrid ligands: a novel tracer concept exemplified by 18F- or 68Ga-labeled rhPSMA inhibitors. J Nucl Med. 2020;61(5):735-742. doi:10.2967/jnumed.119.234922 7. Knorr K, Oh S, Krönke M, et al. Preclinical biodistribution and dosimetry and human biodistribution comparing 18F rhPSMA 7 and single isomer 18F rhPSMA 7.3. EJNMMI Res. 2022;12(8):8. doi:10.1186/s13550-021-00872-w 8. Expert Panel on Urologic Imaging; Froemming AT, Verma S, Eberhardt SC, et al. ACR Appropriateness Criteria® Post-treatment Follow-up Prostate Cancer. J Am Coll Radiol. 2018;15(5S):S132-S149. 9. Oh SW, Wurzer A, Teoh EJ, et al. Quantitative and qualitative analyses of biodistribution and PET image quality of a novel radiohybrid PSMA, 18F-rhPSMA-7, in patients with prostate cancer. J Nucl Med. 2020;61(5):702-709. doi:10.2967/jnumed.119.234609 10. Tolvanen T, Kalliokoski K, Malaspina S, et al. Safety, biodistribution, and radiation dosimetry of 18F-rhPSMA-7.3 in healthy adult volunteers. J Nucl Med. 2021;62(5):679-684. doi:10.2967/jnumed.120.252114